Related Experiment Video
Updated: Mar 11, 2026
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
6.2K
Epigenetic changes as prognostic predictors in endometrial carcinomas
Sanja A Farkas1, Bengt G Sorbe2, Torbjörn K Nilsson3
1a Department of Laboratory Medicine , Örebro University , Örebro , Sweden.
Epigenetics
|November 23, 2016
Summary
Researchers identified novel DNA methylation markers, including TBX2, CHST11, and NID2, in high-risk endometrial cancer. These findings may improve diagnostics and prognostics for this common gynecological malignancy.
Area of Science:
- Gynecologic Oncology
- Epigenetics
- Cancer Biomarkers
Background:
- Endometrial carcinoma is a frequent gynecological malignancy.
- Identifying reliable diagnostic and prognostic markers for high-risk endometrial cancer subgroups remains a challenge.
- Current markers for high-risk groups with poor prognosis are debated globally.
Purpose of the Study:
- To discover novel DNA methylation markers for high-risk endometrial cancer.
- To identify molecular biomarkers associated with unfavorable clinical predictive and prognostic factors.
- To differentiate between high-risk (FIGO-grade 3) and low-risk (FIGO-grade 1) endometrial cancer patient groups.
Main Methods:
- Utilized Illumina Infinium HumanMethylation450 BeadChip array for DNA methylation analysis.
- Analyzed DNA methylation patterns in endometrial cancer patients stratified by risk (FIGO-grade 3 vs. FIGO-grade 1).
- Correlated DNA methylation profiles with key clinicopathological features.
Main Results:
- Identified a distinct DNA methylation signature in high-risk endometrial tumors.
- Discovered potential molecular biomarker genes: TBX2, CHST11, and NID2.
- These genes showed association with unfavorable clinical predictive and prognostic factors.
Conclusions:
- TBX2, CHST11, and NID2 represent potential DNA methylation biomarkers for high-risk endometrial cancer.
- These markers could aid in improving risk stratification and patient management.
- Further validation is warranted for clinical application in endometrial cancer diagnostics and prognostics.
